Teva says yes to M&A; GlycoMimetics snags $57.4M in IPO retry;

@FierceBiotech: Merck clears an FDA panel with its clot-fighting vorapaxar. Story | Follow @FierceBiotech

@JohnCFierce: ICYMI: Roche 's dealmakers at pRED will continue their global shopping spree in 2014. More | Follow @JohnCFierce

@DamianFierce: Sarepta still climbing on renewed hopes for eteplirsen. Article | Follow @DamianFierce

@EmilyMFierce: Per the FDA's new stance on antibacterials, here's a list of household products containing triclosan. | Follow @EmilyMFierce

> Israel's Teva Pharmaceutical ($TEVA) will be a bullish dealmaker under new CEO Erez Vigodman, according to CFO Eyal Desheh. Article

> GlycoMimetics ($GLYC) netted $57.4 million in its second try at an IPO, money it'll use to fund the development of GMI-1271, an early-stage treatment for acute myeloid leukemia. News

> Houston's Bio-Path is raising $10 million to support Liposomal Grb-2, a Phase I treatment for blood cancers. More

Medical Device News

@FierceMedDev: Thermo nabs Chinese approval of $13.6B Life Tech merger. More | Follow @FierceMedDev

@MarkHFierce: Even N.Y. Sen. Chuck Schumer spilled the beans about Carlyle Group's bid for J&J's Ortho Clinical diagnostics arm. Story | Follow @MarkHFierce

@MichaelGFierce: Cynapsus' sublingual strip for severe Parkinson's reduces side effects in a study. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Integra finalizes $235M deal for Covidien's surgical products line. News | Follow @EmilyWFierce

@GalenMoore: Bio-Path Holdings is raising $10M for its cancer drug delivery tech. Release | Follow @GalenMoore

> Medtronic must pay Edwards at least $394M in heart valve patent trial defeat. Report

> Illumina will concoct a companion Dx for an Amgen colon cancer drug. Item

Pharma News

@FiercePharma: FDA: The social media guidance puzzle will be complete by July. More | Follow @FiercePharma

@TracyStaton: Hungary joins the club of EU countries approving Novartis' generic version of GSK's blockbuster Advair. News | Follow @TracyStaton

@EricPFierce: FDA investigator assigned to Europol to fight fakes being hawked online by drug rings. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Allergan rides high on patent backing for key drugs Lumigan and Restasis. Article | Follow @CarlyHFierce

> Actavis is pulling out of China; CEO says it's 'not worth the aggravation.' News

> FDA: The social media guidance puzzle will be complete by July. Story

> Impatient Bidvest prods Adcock for a deal as tussle with rival bidder escalates. Report

> J&J takes Carlyle's $4B offer for its Ortho Diagnostics unit. Item

Pharma Manufacturing News

> Merck recalls all lots of Liptruzet shipped since its May debut. Story

> Ex-Fresenius employee says he was fired for raising red flags. Article

> Premier supports new FDA compounder oversight plan. Report

> FDA assigns an agent to Europol in its fight against fakes. More

> Sources: Ranbaxy asks the FDA to let it make generic Diovan in U.S. News

> Actavis selling China assets as it exits that country. Item

Vaccines News

> CDC, FDA studies link Merck and GSK rotavirus vaccines to bowel blockages. Story

> BIO and Sanofi are pushing the FDA to tweak its drug shortage rule for vaccines. Story

> A Dendreon consultant has raised $8M for a cancer vaccine startup. Story

> Buzz: Merck and Novartis trying to iron out details of their business unit swap. Story

> AC Immune begins first trial of a tau-targeting Alzheimer's vaccine. Story

> Astellas and Takeda continue to advance vaccine strategies. Item